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Abstract
We aimed to compare body segment and bone lengths in glucocorticoid-treated boys with Duchenne muscular dystrophy (DMD)
with healthy controls using dual-energy absorptiometry (DXA) images. Total height (Ht), sitting height (SH), leg length (LL) and
bone lengths (femur, tibia) in boys with DMD and age-matched control boys were measured using DXA. Thirty boys with DMD
(median age 10.0 years (6.1, 16.8)) were compared with 30 controls. SH in DMD was 3.3 cm lower (95% CI − 6.1, − 0.66; p =
0.016). LL in DMDwas 7.3 cm lower (95%CI − 11.2, − 3.4; p < 0.0001). SH:LL of boys with DMDwas higher by 0.08 (95%CI
0.04, 0.12; p < 0.0001). Femur length in DMDwas 2.4 cm lower (95% CI − 4.6, − 0.12; p = 0.04), whereas tibial length in DMD
was 4.8 cm lower (95% CI − 6.7, − 2.9; p < 0.0001). SH:LL was not associated with duration of glucocorticoid use (SH:LL β =
0.003, 95% CI − 0.01 to 0.002, p = 0.72).
Conclusion: Glucocorticoid-treated boys with DMD exhibit skeletal disproportion with relatively shorter leg length and more
marked reduction of distal long bones. As glucocorticoid excess is not associated with such disproportion, our findings raise the
possibility of an intrinsic disorder of growth in DMD.
What is Known
• Severe growth impairment and short stature are commonly observed in boys with Duchenne muscular dystrophy (DMD), especially those treated with
long-term glucocorticoids (GC).
• In other groups of children with chronic conditions and/or disorders of puberty, skeletal disproportion with lower spinal length has been reported.
What is New
•Growth impairment in GC-treated boys with DMDwas associated with skeletal disproportion in relation to age, with lower limbs and distal long bones
affected to a greater degree.
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Abbreviations
DMD Duchenne muscular dystrophy
DXA Dual-energy X-ray absorptiometry
GC Glucocorticoids
Ht Total height
LL Leg length
NSAA NorthStar Ambulatory Assessment
SDS Standard deviation score
SH Sitting height
SHOX Short stature homeobox-containing gene
VC Vertebral column
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Introduction
Severe growth impairment and short stature are common-
ly observed in boys with Duchenne muscular dystrophy
(DMD), especially those treated with long-term glucocor-
ticoids (GC). Several observations point to the possibility
that DMD, itself, may be associated with a growth disor-
der. Approximately, a quarter of boys with DMD are
short prior to initiation of GC [1–3], and growth failure
that pre-dates the initiation of GC therapy has been re-
ported [4]. It is increasingly recognised that the majority
of adolescent boys with DMD who continue on GC may
have persistent hypogonadism. In other groups of chil-
dren with chronic conditions and/or disorders of puberty,
skeletal disproportion with lower spinal length has been
reported [5, 6]. Mechanical stimulation may play a role in
stimulating growth, as inferred from studies in children
with hemiplegic cerebral palsy where leg length discrep-
ancy has been reported [7]. Whilst experimental studies
using in vitro and in vivo models allow evaluation of
longitudinal bone growth [8, 9], clinical studies of bone
length and body proportions in DMD are not available to
the best of our knowledge.
Annual monitoring of bone density using dual-energy
X-ray absorptiometry (DXA) is part of standard care in
DMD [10]. Total body DXA scans can be analysed using
digital analysis tools in the DXA machine to allow mea-
surements of body proportions and bone lengths, similar
to the measurement of vertebral height for vertebral mor-
phometry [11]. The use of DXA to assess body propor-
tion and measure bone length has been shown to be
accurate and precise in adults [12], and recently con-
firmed by our group to be feasible in children with
chronic conditions [13].
The primary aim of this study is to compare body segments
and bone lengths in boys with DMD treated with GC in com-
parison with a group of age-matched healthy controls using
DXA total body images.
Materials and methods
Of the 41 boys with DMD recruited into a prospective
longitudinal study of bone morbidity between January
2016 and March 2017, 30 who were not GC naïve, who
had not discontinued GC or did not have any metal instru-
mentation and/or severe scoliosis based on a Cobb angle of
greater than 20 degrees and had DXA performed on the
Lunar iDXA (GE Lunar Corp, Madison, WI, USA) were
included in this present study. Contractures were defined
by the presence of hip extension greater than − 10 degrees
and/or knee extension greater than − 10 degrees from neu-
romuscular physiotherapist assessment as per NorthStar
Assessment Guidelines. NorthStar Ambulatory Assessment
(NSAA) scores were reported for those who were ambulant,
based on structured physiotherapy assessment at study visits
[14]. NSAA scores range from 0 to a maximum score of 34.
Pubertal assessment was performed by a single independent
assessor (SCW) using the Tanner and Whitehouse method
[15]. Vertebral fractures were diagnosed from DXA lateral
vertebral morphometry.
Thirty out of 94 healthy locally recruited age-matched
boys who had DXA performed as part of a normative
study of DXA bone mineral density was the comparative
group [16]. Controls were individually age matched to be
within 6 months in age with the DMD group. DXA in
the healthy cohort was performed on the Lunar Prodigy
(GE Medical Systems, Waukesha, Wisconsin, USA).
Pubertal assessment in this group was performed using
self-assessment forms.
Both studies were approved by the West of Scotland
ethics committee. Each parent and participant provided
written informed consent/assent prior to study enrolment.
Body segment and bone length measurements using
DXA images of the total body measurement
Body segments (sitting height, total height, lower limb
length, vertebral column length and upper limb length),
body proportion (sitting height to lower limb ratio) and
bone lengths (femur, tibia, humerus and forearm) were
measured using DXA images. Measurements were per-
formed in triplicate on different occasions, by a single ob-
server (KTK), blinded to results from previous measure-
ments. The methodology for measuring sitting height, total
height and lower limbs using DXA has been previously
reported (Supplementary Fig. 1a) [13]. The measurement
with the greatest amount of difference from the median
value of the three measurements for each subject was ex-
cluded. The remainder two measurements were averaged
and used for analysis.
For images where the subject had abducted legs and
equinus foot position (BBent position^), leg length was
defined by measurements of bone lengths. The distances
between the ischium and condyles, condyles and the
talus, and the talus to the sole of the foot were mea-
sured for each lower limb. The average of measure-
ments of both lower limbs was taken as the leg length
(Supplementary Fig. 1b).
Vertebral column was defined as the distance from the
sternum (T2) to the top of the iliac crest (L4). Femur
length was defined as the distance from the femoral head
to the condyles. Tibia length was defined as the measure-
ment between the condyles and the mortise joint.
Humerus length was defined as the measurement from
the top of the humeral head to the base of epicondyles.
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Forearm bone length was defined as the measurement
from the radial head and radial/ulna styloid processes.
The sum of the humerus and forearm was taken as the
upper limb length (Supplementary Fig. 1c).
Statistical analyses
All statistical analysis was performed using IBM SPSS 21
(SPSS Inc., Chicago). Results were expressed as median
(range) given the relatively small sample size, and the majority
of the data were not normally distributed.
Two-way mixed effect intraclass correlation (ICC) was
used to evaluate the intra-observer agreement between
body proportion and bone length measurements.
Relative technical error of measurement (rTEM) was cal-
culated using the remaining two DXA measurements,
following removal of the measurement with the greatest
amount of difference from the median value of the three
measurements. Differences between body proportions
and bone lengths in DMD and healthy controls were
evaluated using linear regression following adjustment
pubertal status (pre-pubertal vs pubertal—pre-pubertal,
i.e. Tanner stage 1 as reference category). p < 0.05 was
considered statistically significant.
Results
Demographics
Table 1 shows demographics of the boys with DMD and
healthy controls. There were no differences in age between
the two groups. Almost 60% of the healthy controls were
pre-pubertal, whereas the 26 (87%) boys with DMD were
pre-pubertal. Two (6.7%) boys with DMD were in Tanner
stages 2/3, and two (6.7%) were in Tanner stages 4/5. Boys
with DMD were shorter and had a higher body mass index
(BMI) SDS compared with healthy controls (Table 1). Two of
the boys with DMD were on testosterone therapy for a dura-
tion of 1.5 and 2.0 years at the study visit. None were on
growth hormone therapy. Out of the 30 boys with DMD, 20
had no hip and knee contractures, all of whom were still
ambulant.
Reproducibility of DXA measurements
A high degree of reproducibility was found for all mea-
surements in both the DMD and control groups, with ICC
ranging between 0.927 and 0.998 in controls and 0.975
and 0.999 in boys with DMD (Supplementary Table 1).
Table 1 Baseline demographics
of boys with DMD and healthy
controls
Controls DMD p value
(n, 30) (n, 30)
Age 10.2 (6.3–16.9) 10.0 (6.1–16.8) 0.97
Pubertal stage (%) 0.02
Pre-pubertal 17 (57%) 26 (87%)
Pubertal 13 (43%) 4 (13%)
Height SDS + 0.3 (− 1.4 to + 2.5) − 1.7 (− 7.0 to + 1.7) < 0.001
BMI SDS + 0.6 (− 1.3 to + 1.8) + 2.0 (− 1.4 to + 4.0) < 0.001
Steroid duration (years) 7.1 (1.3 to 15.2) –
Steroid dose* (mg/m2/day) 72.7 (21.1–184.3) –
Pulsed steroid treatment 3 (10%) –
Testosterone treatment 2 (7%) –
Bisphosphonate 10 (33%) –
Vertebral fractures 14 (47%) –
Non-ambulant 10 (33%) –
NSAA score ** 26.5 (8 to 33)
Hip/knee contractures 10 (33%)
Bone age (years) 9.5 (5.0–16) –
DMD, Duchenne muscular dystrophy; SDS, standard deviation score; BMI, body mass index; NSAA, NorthStar
Ambulatory Assessment
Results are presented as median (range)
*Steroid dose reported as hydrocortisone equivalent: prednisone 1 mg = hydrocortisone 4 mg; deflazacort 1 mg =
6 mg hydrocortisone. Dose is half if the patient is on pulsed treatment
**Maximal score of NSAA score is 34 and consists of 17 domains of lower limb muscle function. The assess-
ments are performed by trained neuromuscular physiotherapist and are results of the 20 ambulant boys with DMD
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Intra-observer variability of the remaining two measure-
ments showed excellent agreement with the rTEM below
1% for all measurements. rTEM for tibia and forearm
measurements in the DMD group was 1.2%, respectively.
Body segments and body proportion in DMD
compared with controls
Height and body segments were lower in DMD com-
pared with healthy controls in unadjusted analysis
(Fig. 1a–f). Body proportion as assessed by sitting height
to leg length ratio was higher in DMD compared with
healthy controls in unadjusted analysis (Fig. 1e).
Table 2 shows the results of height and body segments
in boys with DMD compared with healthy controls after
adjusting puberty. The height of boys with DMD was
10.7 cm lower (95% CI − 17.1 to − 4.3). Sitting height
and vertebral column were 3.3 cm (95% CI − 6.1 to −
0.66) and 1.7 cm lower (95% CI − 3.2 to − 0.31), respec-
tively. In contrast, the leg length of boys with DMD was
9.9 cm lower (95% CI − 13.1 to − 6.6). Median percentage
difference for sitting in boys with DMD in comparison
with controls was − 6.5% (− 24% to + 6.7%). In contrast,
median percentage difference for leg length in boys with
DMD in comparison with controls was − 13% (− 46% to
+ 13%). Sitting height to leg length ratio of boys with
DMD was higher by 0.08 (95% CI 0.04 to 0.12). The
upper limb of boys with DMD was 3.6 cm lower (95%
CI − 6.2 to − 0.97).
Sub-analysis of the 20 boys with DMD with no hip and/or
knee contractures with 20 age-matched healthy controls
showed identical results in similar adjusted regressionmodels.
The height of the subset of these boys with DMDwas 11.5 cm
lower (95% − 1.97 to − 3.4, p = 0.007). Sitting height and
vertebral column of these boys with DMD were 4.2 cm
(95% CI − 7.7 to − 0.69, p = 0.02) and 2.4 cm lower (95%
CI − 4.2 to − 0.56, p = 0.012), respectively. Similarly, leg
length of these boys with DMD was 7.4 cm lower (95% CI
− 12.4 to − 2.4, p = 0.005). Median percentage difference for
sitting height in this subset of boys with DMDwas − 9.2% (−
24% to + 6.8%). In contrast, median percentage difference for
leg length in this subset of boys with DMDwas − 16% (− 46%
to + 1.7%) and the sitting height to leg length ratio of these
boys with DMD was higher by 0.07 (95% CI 0.02 to 0.12).
Bone lengths in DMD compared with controls
All bone lengths were lower in DMD compared with healthy
controls in unadjusted analysis (Fig. 2).
Table 2 shows the results of bone lengths in boys with
DMD compared with healthy controls after adjusting for pu-
berty. Femur and tibia lengths of boys with DMDwere 2.4 cm
(95%CI − 4.6 to − 0.12] and 4.8 cm lower (95%CI − 6.7 to −
2.9) respectively. Median percentage difference for femur and
tibial length in boys with DMD in comparison with controls
were − 12% (− 41% to + 19%) and − 23% (− 53% to + 9.4%),
respectively. Forearm bone lengths of boys with DMD were
2.7 cm lower (95% CI − 4.0 to − 1.3). No significant differ-
ence was observed in humerus length in boys with DMD
Fig. 1 Anthropometry of boys with DMD in comparison with healthy
controls (unadjusted analysis). a Ht in boys with DMD compared with
controls. b SH in boys with DMD compared with controls. c VC in boys
with DMD compared with controls. d LL in boys with DMD compared
with controls. e SH:LL ratio in boys with DMD compared with controls. f
UL in boys with DMD compared with controls. Statistical analysis was
performed using linear regression analysis. Empty squares represent boys
with DMD and solid circles represent healthy control boys. Solid lines
represent the lines of best fit. p values are for differences between DMD
and control β slopes. DMD, Duchenne muscular dystrophy; Ht, total
height; SH, sitting height; VC, vertebral column; LL, leg length; UL,
upper limb
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compared with controls. Median percentage difference for hu-
merus and forearm bone lengths in boys with DMD in
comparison with controls was − 7.5% (− 34% to + 22%) and
− 16% (− 52% to + 9.6%), respectively.
Similarly, sub-analysis of the 20 boys with DMD with no
hip and/or knee contractures with 20 age-matched healthy
controls showed identical results for bone lengths using ad-
justed regression models. Tibia lengths of this subset of boys
with DMD were 4.4 cm lower (95% CI − 6.8 to − 2.0, p =
0.001). No significant difference was observed in femur
length in boys with DMD compared with controls. Median
percentage difference for tibial and femur lengths in this sub-
set of boys with DMD in comparison with controls was − 21%
(− 54% to + 1.3%) and − 8.4% (− 41% to + 7.6%), respective-
ly. Median percentage difference for humerus and forearm
bone lengths in this subset of boys with DMD in comparison
with controls was − 7.2% (− 32% to + 13%) and − 16% (−
52% to − 1.4%), respectively.
Association of sitting height to leg length ratio
in DMD with GC and mobility score
No association was observed between duration of GC and
sitting height to leg length ratio (β = 0.003, 95% CI − 0.01 to
0.002, p = 0.72) and dose of GC in hydrocortisone equivalent
dose (β = 0.00, 95% CI − 0.0001 to 0.001, p = 0.09), adjusted
for age and pubertal status. No association was observed
Table 2 Body proportion and bone length differences between boys
with DMD and controls (adjusted model)
β (95% CI) r2 p value
Body proportions
SH − 3.3 (− 6.1 to − 0.66) 0.44 0.016
LL − 7.3 (− 11.2 to − 3.4) 0.48 < 0.0001
UL − 3.6 (− 6.2 to − 0.97) 0.45 0.008
VC − 1.7 (− 3.2 to − 0.31) 0.38 0.018
Height − 10.7 (− 17.1 to − 4.3) 0.49 0.001
SH:LL 0.08 (0.04 to 0.12) 0.36 < 0.0001
Bone lengths
Femur − 2.4 (− 4.6 to − 0.12) 0.37 0.04
Tibia − 4.8 (− 6.7 to − 2.9) 0.56 < 0.0001
Humerus − 0.81 (− 2.3 to 0.64) 0.33 0.268
Forearm − 2.7 (− 4.0 to − 1.3) 0.54 < 0.0001
DMD, Duchenne muscular dystrophy; SH, sitting height; LL, leg length;
UL, upper limb; VC, vertebral column
Linear regression models were constructed with pubertal status (pre-pu-
bertal vs pubertal—pre-pubertal as reference category) and disease cate-
gory (control vs DMD—control as reference category) as independent
factors
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Fig. 2 Bone lengths of boys with DMD in comparison with healthy
controls (unadjusted analysis). a Femur length in boys with DMD
compared with controls. b Tibial length in boys with DMD compared
with controls. c Humerus length in boys with DMD compared with
controls. d Forearm length in boys with DMD compared with controls.
Statistical analysis was performed using linear regression analysis. Empty
squares represent boys with DMD and solid circles represent healthy
control boys. Solid lines represent the lines of best fit. p values are for
differences between DMD and control β slopes. DMD, Duchenne
muscular dystrophy
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between NSAA score at study visit and body disproportion
(β = − 0.002, 95% CI − 0.006 to − 0.002, p = 0.23) in the
subset of boys without contractures, adjusted for age and
pubertal status.
Discussion
This study used DXA total body images to evaluate body
segments and bone lengths and demonstrated for the first time
that skeletal disproportion exists in boys with DMD treated
with GC. In these boys, the deficit was greater in the lower
limbs compared with the spine. Furthermore, distal long bones
in the lower and upper limb were more affected in DMD
compared with healthy controls.
In our present report, we showed that measurement of
bone lengths in DMD is feasible using total body images
from DXA scans, extending our recent report in children
with chronic conditions [13]. The Lunar GE iDXA ma-
chine, used in our current study, utilises a narrow-angle
fan X-ray beam to obtain images. Fan beams, such as the
wide fan beam used in Hologic machines may lead to
distortion of images in up to 37% of bone mineral density
measurements, which may lead to parallax errors [17, 18].
However, Lunar DXA machines use a multi-view image
reconstruction technique to reduce distortion and reduce
magnification errors [19]. Parallax errors in the DXA im-
ages are an issue with measurement of height using this
method as some boys with DMD may have hip and knee
contractures and are therefore unable to lie flat. In our
sub-analysis of those who did not have lower limb con-
tractures, greater impairment in the lower limb and distal
bones was also observed, demonstrating that our observa-
tions in the whole group were not due to image distortion
caused by lower limb contractures.
Short stature is a prominent feature in boys with DMD,
with normal length observed at birth, followed by a gradual
deceleration in growth after the first few years of life prior to
the introduction of GC [2]. Although there is no doubt that
short stature is exacerbated by the use of GC in DMD [20, 21],
supraphysiological doses of GC in juvenile arthritis do not
lead to skeletal disproportion [22]. In our study, no relation-
ship was observed between glucocorticoid duration and dose
with body proportion after adjusting for age and pubertal sta-
tus. This provides further evidence that factors other than GC
may play a role in the disproportion observed in our study.
Future studies should evaluate body segments in DMD prior
to the initiation of GC and following therapy. Clinical practice
over the last decade and in accordance with the international
standards of care recommends the introduction of GC inDMD
from approximately 3–4 years, an age where DXA for bone
monitoring is often not performed due to lack of normative
bone mineral density data in those < 5 years [23]. In our clinic
of 51 boys with DMD in 2018, none is GC naive.
The underlying genotype may be an explanation for the
skeletal disproportion in DMD. Children with short stature
homeobox-containing gene (SHOX) deletion are known to
have disproportionately shorter leg length and distal long bone
abnormalities [24]. SHOX is exclusively expressed in the first
and second pharyngeal arches and in the developing distal
limb bones of human embryos [25], resulting in compromised
linear growth and unbalanced premature growth plate fusion
of the distal limb bones [26, 27]. The dystrophin gene is lo-
cated in the Xp21 region, adjacent to the SHOX gene, which is
located in the pseudoautosomal region of Xp22. It is possible
that the molecular defects in the Xp21 regionmay also involve
adjacent genes in the Xp22 region, causing the abnormal low-
er limb growth patterns [2]. However, the deletion of Xp22 as
part of a contiguous gene deletion syndrome is only found in a
minority of boys with DMD [28]. Two studies in DMD have
identified that short stature is more common in boys with
DMD with distal deletions suggesting a genotype effect on
linear growth in DMD [1, 29]. Both studies did not evaluate
body segments.
Another possible explanation of the observation of dispro-
portionately shorter legs in DMD is the lack of mechanical
stimulation due to the underlying myopathy. Postnatal bone
growth is dependent on an intact ‘muscle-bone’ unit, and the
development of children’s load-bearing bones depends strong-
ly on muscle mass and strength [30]. In healthy children,
earlier age of walking predicts greater bonemass in later child-
hood and adolescence, although these studies did not evaluate
the impact on longitudinal bone growth [31, 32]. In rat
models, osteocytes at the endosteal side of the shaft and the
inner lamellae are mechanosensitive. The absence of mechan-
ical load in these animal models resulted in decreased bone
formation and longitudinal bone growth via a reduction in
local IGF-1 production [33–35]. Studies in children with ce-
rebral palsy showed that tibial length is reduced by up to 5 cm,
with greater reduction in tibial length in those with more se-
vere CP and increasing age [36]. In our sub-analysis, we did
not find an association with the NSAA scores and dispropor-
tion at the study visit. However, longitudinal assessments of
muscle function are required to provide greater insight into the
relationship with growth in the lower limb of boys with DMD,
as reduction in weight-bearing activity in these boys may con-
tribute in part to our observations.
There are several limitations of our current study with a
relatively small sample size. The cross-sectional nature of
the study precluded us frommeaningful analysis and interpre-
tation of disease and treatment factors on bone length and
disproportion. Images of the DMD and control groups were
performed using different Lunar DXA machines. However,
repeatability of measurements in both DMD and healthy con-
trols was in the excellent category. As BMD correlation
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between these two instruments was shown to be excellent with
comparable precision previously, we believe that this should
not introduce significant intergroup bias [37]. Pubertal assess-
ment was not performed in the similar manner in the boyswith
DMD and healthy controls. However, we believe our study
identified new insights into growth impairment in DMD and
future studies to elucidate the underlyingmechanisms are now
needed.
Conclusion
This study showed for the first time that growth impairment in
GC-treated boys with DMD was associated with skeletal dis-
proportion, with lower limbs being affected to a greater degree
compared with the spine, and that distal long bones were more
affected. Further, the disproportion appears to increase with
age. As skeletal disproportion is not a known finding with pae-
diatric GC excess, our observation of disproportionate bone
lengths in boys with DMD raises the question of whether
DMD is an intrinsic and localised disorder of growth or dimin-
ished growth of the extremities secondary to the myopathy,
which may be best investigated in future experimental studies.
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